Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial

A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029518

Enrollment

Unknown

Registered

2020-02-03

Start date

2020-02-04

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

(ordinary) Western medicine group:Use the (ordinary) western medicine treatment plan in "the diagnosis and treatment plan of new coronavirus infection pneumonia" issued by the National Health Commiss

(ordinary) Chinese and Western Medicine Group:Use the (ordinary) TCM clinical prescription combined with the western medicine treatment plan in "the diagnosis and treatment plan of new coronavirus

(severe) Western medicine group:Use the (severe) TCM clinical prescription combined with the western medicine treatment plan in "the diagnosis and treatment plan of new coronavirus infection pneumonia

(severe) Chinese and Western Medicine Group:Use the(severe)TCM clinical prescription combined with the western medicine treatment plan in "the diagnosis and treatment plan of new coronavirus infection

Eligibility

Sex/Gender

All

Age

14 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients who meet the diagnostic criteria of the common type of confirmed cases (the initial stage of clinical treatment of traditional Chinese medicine) or the severe cases of confirmed cases (the middle stage of clinical treatment of traditional Chinese medicine); (2) The cases of common type (the initial stage of clinical treatment of traditional Chinese medicine) belong to the type of cold-dampness stagnant lung; (3) The confirmed cases were severe (in the middle stage of clinical treatment of traditional Chinese medicine). (4) The patients knew and agreed to participate in this study.

Exclusion criteria

Exclusion criteria: (1) The critically ill patients in the diagnosis and treatment program of pneumonia with new coronavirus infection issued by the National Health Commission; (2) It is not suitable for patients who take traditional Chinese medicine decoction; (3) Those with other serious organ diseases or mental diseases; (4) Those who are allergic to or have contraindications to the drugs involved in the study scheme.

Design outcomes

Primary

Measure	Time frame
Recovery time;Ratio and time for the general type to progress to heavy;Ratio and time of severe progression to critical or even death;	—

Secondary

Measure	Time frame
Improvement of TCM syndromes;Relief of clinical symptoms (fever, fatigue, gastrointestinal discomfort, etc.) and duration;Lung HRCT score improvement;Average length of hospital stay;Adverse event rate;Quality of life (SF 36);	—

Countries

China

Contacts

Public ContactWen Chengping

Zhejiang Chinese Medical University

wengcp@163.com+86 13906514781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026